News and Trends 18 Jan 2017 Evotec launches New Biotech to tackle the Most Deadly Diseases Evotec has backed the foundation of Fibrocor, a Canadian company that will work on fibrosis, the underlying cause of some of the most deadly diseases. Fibrocor was launched yesterday in Toronto with €2M (CDN 2.8M) from the successful German biotech CRO Evotec and the Canadian non-profit MaRS Innovation. Evotec will provide all drug discovery activities […] January 18, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 18 Jan 2017 New Combo Therapy for Type 2 Diabetes to Sweep Europe Zealand Pharma and its partner Sanofi have made it to the European market with a new combination therapy to treat type 2 diabetes. Suliqua, a treatment for type 2 diabetes, has received marketing authorization in Europe. This feat has earned Zealand Pharma a €9.4M ($10M) payment from its partner Sanofi. The big pharma is responsible […] January 18, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 18 Jan 2017 It’s Not Just Regulations: 9 Other Reasons Advanced Therapies Fail For advanced therapy medicinal products (ATMPs), the regulatory process is a major challenge to reach the market; but it’s only part of the picture. Here are the top 9 other pre-approval reasons these cell and gene therapies fail. Sound Scientific Rationale + Good Product = Successful Outcome.” Paula Salmikangas, Committee for Advanced Therapies (CAT) Chairman […] January 18, 2017 - 7 minutesmins - By Timothé Cynober Share WhatsApp Twitter Linkedin Email
More News! 17 Jan 2017 Nanoparticles from Car Tailpipes could Activate Viruses in the Lungs Nanoparticles produced by burning fossil fuels could promote viral infections by activating latent viruses in our lungs; what are the consequences? We all know that breathing the traffic smoke is not good for our health. Now, researchers from the Helmholtz Zentrum in Munich have discovered a process that makes it even more dangerous than initially […] January 17, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 17 Jan 2017 This Herpes Cure is Proving to Work Better than its Predecessors AiCuris’ candidate pritelivir has shown to perform better than current standard antiviral treatments against genital herpes in Phase II trials. AiCuris, leading the development of treatments for infectious disease, has completed a Phase II trial in which its candidate pritelivir outperformed the current standard care for genital herpes. When compared to the antiviral drug valacyclovir, […] January 17, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 17 Jan 2017 This Leading Gas Distributor from France is Going Bio Global Bioenergies and Butagaz will collaborate to develop and incorporate renewable energy sources into France’s energy systems. Butagaz, a gas distributor from France, is partnering with Global Bioenergies, a synbio company in Paris that produces biofuel with renewable sources. Butagaz will support Global Bioenergies’ industrial development in exchange for the first batches of bio-isobutene the […] January 17, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Best in Biotech 17 Jan 2017 Here are 15 Women Leading in European Biotech After listing the key people to meet in the biotech hotspots of Munich and the Golden Triangle, we looked for women who are particularly successful in biotech across the continent. The industry has been accused of having a big problem with sexism and, as we’ve written about in the wake of the JP Morgan party […] January 17, 2017 - 7 minutesmins - By Denise Neves Gameiro Share WhatsApp Twitter Linkedin Email
News and Trends 16 Jan 2017 German Antibody for Cancer Diagnostics catches an Australian Eye Wilex is selling Telix Pharmaceuticals its radiolabeled antibody for cancer applications, Redectane, to focus on the development of ADCs instead. The Australian Telix Pharmaceuticals has closed a license agreement with Wilex, in Germany, for the worldwide rights to Redectane, an antibody with diagnostic applications in renal cancer. The antibody, Rencarex (girentuximab), which binds to the […] January 16, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 16 Jan 2017 Merck partners with Big Data Unicorn to help Cancer Patients Merck will use Palantir’s big data software to improve drug development and patient services, starting with cancer treatments. Merck will step up its data analytics capabilities in partnership with Palantir. The US company, co-founded by PayPal billionaire Peter Thiel, provides data integration and analysis software that Merck plans to use to improve patient care and […] January 16, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 16 Jan 2017 The UK Steps Up its Game in Automated CRISPR Gene Editing Horizon Discovery now has full access to CRISPR technology and will develop an automated gene editing platform in collaboration with Solentim. Horizon Discovery, based in Cambridge, UK, uses gene editing technology to create custom cell lines for research. To step up its game, the company has upgraded its existing license with ERS Genomics‘ to obtain […] January 16, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
More News! 14 Jan 2017 This Bioartist is Exhibiting Living Portraits of her own Daughters Gina Czarnecki raises questions about identity and ownership of our own bodies through living artwork that once used to form part of other human beings. Gina Czarnecki, based in London, has used her own daughters’ cells to create unique pieces of art. In her project ‘Heirloom‘, recently exhibited at Medical Museion Copenhagen and created in collaboration […] January 14, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Startup Scout 13 Jan 2017 The Good, the Bad and the Cancer-Fighting Macrophage We decided to stick around England this week and made a short trip from London to visit the young biotech Macrophage Pharma. The company is developing immuno-oncology technology that could turn ‘bad’ tumor-associated macrophages into ‘good’, cancer-fighting cells. City: Berkhamsted, UK (near London) Founded: 2014 Employees: 1-10 Financial data: €10.38M total raised Mission: Macrophage Pharma develops next-generation immunotherapies […] January 13, 2017 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email